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Abstract 
Background: In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) advises on the 
reimbursement of drugs to be subsidised through the Pharmaceutical Benefits Scheme (PBS). This study aims to 
provide insights into the PBAC process and key considerations regarding the reimbursement of MS drugs in 
Australia.  
Methods: The factors considered by the PBAC and its advice on whether to reimburse a drug are documented in 
public summary documents (PSDs). Qualitative content analysis of PSDs was conducted for all MS drugs 
considered by the PBAC between January 2006 and January 2018. Key issues identified by the PBAC were 
extracted and categorised. Common issues were identified and compared between drugs indicated for MS. 
Results: A total of 23 submissions were evaluated relating to 13 MS drugs. Eight were recommended for 
reimbursement; an approval rate of 35% per submission and 62% per drug. Approval rates were higher for 
disease modifying treatments (73% per drug) than for other drugs (0% for nabiximols and fampridine 
submissions). The most frequently discussed issues in PSDs, irrespective of PBAC decision, were: (1) the 
validity of the indirect comparisons formed (n=11); (2) the validity of the approach to obtain utilities (n=6); (3) 
the lack of appropriate/long-term safety data (n=8); and (4) the time horizon used in the economic models (n=3). 
Conclusion: A small but important number of issues have been consistently identified by the PBAC in relation 
to submissions for reimbursement of MS drugs. Drug developers and clinical trial investigators who are aware 
of these issues will be able to anticipate data requirements for reimbursement decision-making and thus 
potentially improve the evidence submitted for listing of MS drugs in Australia. 
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Abbreviations 
CHMP, Committee for Medicinal for Human Use; ICER, incremental cost-effectiveness ratio; MCID, minimal 
clinically important difference; MS, multiple sclerosis; PBAC, Pharmaceutical Benefits Advisory Committee; 
PBS, Pharmaceutical Benefits Scheme; PSD, public summary document; QALY, quality-adjusted life year; 
RPBS, Repatriation Pharmaceutical Benefits Scheme; RRMS, relapsing-remitting multiple sclerosis; RSA, risk-
sharing arrangement. 
 
1. Introduction 
In the past two decades, remarkable advances have been made in treatment options for multiple sclerosis (MS) 
[1]. These advances have been made hand-in-hand with considerable increases in spending on MS treatments by 
patients, healthcare payers and society as a whole [2]. For example, in Australia, the number of patients 
accessing government-subsidised drug treatment for relapsing-remitting MS (RRMS) increased from 8,630 in 
2006 to 15,704 in 2014 [3]. Based on the published prices for RRMS therapies, this resulted in an increase in the 
net cost to the Australian Commonwealth from AUD$91m in 2006 to over AUD$288m in 2014 [3]. 
 
In Australia, drug reimbursement is provided through the Pharmaceutical Benefit Scheme (PBS), a scheme 
which aims to provide universal, affordable access to prescription medicines. Before drugs can be listed on the 
PBS, they must be assessed by the Pharmaceutical Benefits Advisory Committee (PBAC), an expert advisory 
committee which evaluates pharmaceuticals for their comparative clinical effectiveness, safety, and cost-
effectiveness. Under Australian legislation, the PBAC is responsible for assessing requests to list new drugs, as 
well as significant changes to currently listed drugs on the PBS [4,5]. PBAC recommendations enable the 
Australian Government to determine which drug technologies provide good value for money and should 
therefore be publicly subsidised [6]. 
 
The PBAC’s recommendations are made transparent to the public by publishing them online as public summary 
documents (PSDs). The purpose of the PSDs is to provide contextual information pertaining to each 
recommendation. Albeit they are limited in terms of the amount and depth of information published, PSDs 
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provide insight into the factors and trade-offs the PBAC noted in arriving at its recommendations. They 
therefore represent a valuable source of information, allowing various stakeholders to learn about the issues of 
importance during the PBAC process [7,8]. 
 
Given the rapid pace of advancement in MS treatments, it is worth studying the issues PBAC considered in 
arriving at recommendations regarding MS drug reimbursement. Internationally, MS patients and their health 
care professionals have expressed concern about unmet needs in MS management, and barriers to personalised 
medicine due to current reimbursement policies [9]. While the PBAC’s recommendations impact which drugs 
will get reimbursed, not much is known about the key hurdles within the PBAC processes for MS drugs to be 
listed speedily for access by the Australian public.  
 
This study provides a review and descriptive analysis of PSD’s for MS treatments. The project aims to provide 
insights into the reimbursement process and key considerations by the PBAC regarding MS drugs. The results 
may facilitate understanding by clinicians, drug manufacturers and other stakeholders regarding the factors that 
influence reimbursement approval for MS drugs in Australia. 
 
 
2. Methods 
Current pharmacological treatment options for MS drugs were identified through the Australian Medicines 
Handbook 2017, the Australian Therapeutic Guidelines and the MS Australia website 
(https://www.msaustralia.org.au/about-ms/medications-treatments). PSDs of the identified drugs were obtained 
via the PBS Department of Health website under the heading “Public Summary Documents by Product”, 
accessed in March 2017 and updated in March 2018. 
Inclusion criteria were that the drug needed to have been considered by the PBAC between January 2006 and 
January 2018 and explicitly requested PBS listing as a treatment for MS (any stage). Treatments used for MS 
patients but where the submission to the PBAC did not specifically request MS as the indication (e.g. botulinum 
toxin type A, Botox®) were excluded. All relevant PSDs for MS drugs were selected, independent of whether 
they were a major or a minor submission
1
. 
 
A range of information items was extracted from each selected PSD (see Table 1). For each item, the following 
was extracted: (1) what was included in the sponsor’s2 submission (e.g. which comparators were proposed in the 
submission), (2) did the PSD cite any issues raised by the PBAC related to this item, and (3) where issues were 
raised, what were the particular matters of concern for the PBAC as cited in the PSD. For each of the 
information items, key issues were extracted and categorised into themes. Differences and similarities between 
drugs in how those themes emerged were explored. Extracted information was first recorded in Microsoft Word 
2016 and later tabulated in Microsoft Excel 2016. 
 
The main issues identified by the PBAC were described and summarised per variable according to the themes 
that emerged. Data extraction and coding was performed by YHLP and cross-checked by NvdL to ensure 
completeness and consistency. Discrepancies were revisited by YHLP and re-checked by NvdL to confirm their 
resolution. 
 
Table 1. Key information items extracted from PSDs, and their meaning. 
Variables Meaning as defined for the purposes of this paper 
Comparator The existing health technology (or current clinical management) that will be 
replaced should the new health technology be implemented as proposed. 
Comparison(s) The set(s) of drugs (proposed health technology and comparator) that were 
compared in the analyses. 
                                                          
1
 According to the procedure guidance for listing medicines on the Pharmaceutical Benefits Scheme, major submissions generally relate to 
requests for the listing of a new medicine or vaccine, a new indication for a currently listed medicine, or to make material changes to a 
currently listed indication where an economic model is required to support a claim of cost-effectiveness, cost-utility or cost-minimisation. 
Minor submissions generally relate to requests to change existing listings that do not change the population or cost-effectiveness of the 
treatment, or the listing of a new form or strength of an already-listed medicine that has a bioequivalence or equivalence statement from the 
Therapeutic Goods Administration. 
2
 The “sponsor” of a submission can be a pharmaceutical company or another organisation or individual supporting the preparation of the 
submission. 
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Key clinical endpoints The main outcome(s) obtained from the clinical studies, e.g. annualised relapse 
rate. 
MCID  The smallest difference in an outcome which patients perceive as beneficial or 
detrimental.  
Clinical claim Assertion made by the sponsor regarding the effectiveness and/or safety of the 
health technology compared to its comparator (e.g. “non-inferior” or “superior”).  
Economic analysis Type of economic evaluation performed (e.g. “cost-effectiveness analysis” or 
“cost-minimisation analysis”). 
Modelling Decision-analytic modelling compares the expected costs and consequences of 
decision options by synthesising information from multiple sources and applying 
mathematical techniques. 
Cycle length Frequency with which a decision-analytic model (e.g. a Markov model) determines 
the costs and outcomes associated with an intervention. This impacts the precision 
of the model with respect to the timing of the events in number of 
days/weeks/months/years. 
ICER The incremental costs of the health technology compared to its comparator, 
divided by the incremental outcomes of the health technology compared to its 
comparator. 
Number and types of health states Number and types of distinct phases of a disease or treatment that are included in 
the decision model. 
Key assumptions Main aspects of the model that are uncertain and influence the results. 
RSA  Any arrangement suggested to adequately manage risks (i.e. uncertainty in overall 
cost to PBS/RPBS, cost-effectiveness, or extent of overall gain in health outcomes) 
by sharing these risks between the sponsor and the Australian Government. 
Financial impact  Projected utilisation and annual cost to the Australian Government. 
Outcome of submission Recommended, rejected or deferred. 
Abbreviations: ICER, incremental cost-effectiveness ratio; MCID, minimal clinically important difference; PBS, 
Pharmaceutical Benefits Scheme; PSD, public summary document; RPBS, Repatriation Pharmaceutical Benefits 
Scheme; RSA, risk-sharing arrangement. 
 
 
3. Results 
Since 2006, a total of 23 submissions, covering 13 drugs, were considered by the PBAC for the treatment of MS 
in Australia. Seventeen submissions sought listing (or changes to the listing) for treatment of RRMS. Six 
submissions sought listings in other MS settings; one (glatiramer acetate) for the treatment of patients with a 
demyelinating event indicative of MS, one for primary progressive MS, and one submission (interferon beta – 
1b) requested a review of the eligibility criteria of drugs for the treatment of MS to allow for the use of the 
McDonald criteria as opposed to the Poser criteria to determine patient eligibility to access treatment. Three 
submissions sought listing for MS-related symptoms: one (nabiximols) for the treatment of moderate to severe 
spasticity due to MS, and two (both for fampridine) for the symptomatic improvement of walking ability in 
ambulatory MS patients. 
Figure 1 shows a timeline for the consideration of MS drugs over the last eleven years. Before 2006, the PBAC 
had already funded access to three beta-interferons (Avonex, Betaferon and Rebif) and to daily injections of 
Copaxone. From 2006 onwards, eight more drugs were recommended for listing. Thirteen submissions were 
rejected; for two drugs (fingolimod and daclizumab), the decision was deferred. The resulting approval rates 
were 35% per submission and 62% per drug. The mean number of submissions per drug was 1.8. Teriflunomide 
had the highest number of submissions (n=3). 
Approval rates were higher for disease modifying treatments (DMTs) than for other drugs. For the latter, none 
of the three submissions (one for nabiximols, two for fampridine) resulted in a recommendation for 
reimbursement: a 0% approval rate. For the DMTs, approval rates were 40% per submission and 73% per drug. 
While daclizumab was considered by the PBAC (July and November 2016), marketing authorisation for this 
product was recently withdrawn worldwide, following safety issues [10]. Cladribine, previously approved for 
marketing in Australia but rejected for reimbursement in March 2011, has been subsequently withdrawn. 
Recently, it has been reintroduced but was rejected for reimbursement in November 2017 [11].   
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Figure 1. Multiple sclerosis drugs considered by the PBAC since 2006, and outcome of their evaluation (green 
= recommended, yellow = deferred, red = rejected). Open boxes with an (R) signify that this was not the first 
time a submission for this drug was considered. 
 
In the PSDs of 22 of 23 submissions, the PBAC indicated issues with one or more of the following: the main 
comparator, secondary comparator(s), type of studies performed, key endpoints, the MCID, the clinical claim 
with respect to effectiveness and safety, the economic evaluation, the estimated ICER, number and type of 
health states, key data used, the proposed risk-sharing agreement and/or the financial estimations. For one 
submission (glatiramer acetate, March 2015), no issues were identified in the PSD. This was a minor submission 
requesting listing for an additional strength of the drug. 
The issues raised by the PBAC were categorised and four themes of common clinical and economic issues 
emerged: the validity of the indirect comparison, the validity of the approach used to determine quality of life 
(including the claim that disutility is associated with injectable drugs), the lack of appropriate safety data and the 
time horizon used in the economic model. Each of these themes is discussed below.    
3.1. Indirect comparisons 
The PBAC addressed issues regarding the validity of the indirect comparison in eleven submissions: two for 
natalizumab (November 2006 and November 2007), one for fingolimod (March 2011), two for cladribine 
(March 2011 and July 2017), one for dimethyl fumarate (July 2013), two for teriflunomide (November 2012 and 
July 2013), two for daclizumab (July and November 2016), and one for ocrelizumab (July 2017). The issues 
raised by the PBAC regarding indirect comparisons can be further categorised into two sub-themes: the 
comparability of the trials used to inform the comparison; and the basis for claims of non-inferiority derived 
from those comparisons.  
In the respective PSDs, the PBAC highlighted the differences between the study populations in the trials used 
for the indirect treatment comparisons as the major source of validity issues of those indirect comparisons. In 
the absence of a head-to-head randomised study, an indirect comparison can be made to compare an intervention 
and comparator(s). The validity of an indirect comparison depends on the similarity of the study populations in 
the included trials [12].  
The November 2006 PSD for natalizumab indicated that the patients recruited in the trials informing the indirect 
comparison were insufficiently comparable at baseline, given that the annualised relapse rate at one year in the 
placebo group of the interferon trial was around double the risk in the placebo group of the AFFIRM trial (the 
key trial for natalizumab). The PSD for cladribine (March 2011) also noted the difference in annualised relapse 
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rate reported in the placebo arms of the trials (0.33 in CLARITY versus 1.28 in PRISMS). Similarly, for 
teriflunomide, the PBAC noted that the placebo response rates varied between the trials, and that there were 
differences in selection criteria and baseline clinical characteristics. Differences in results for placebo treatment 
groups between trials were also mentioned as an issue for daclizumab (July and November 2016) and a wide 
range of exchangeability issues [13] were listed. Exchangeability issues also hampered interpretation of results 
for ocrelizumab (July 2017) and fingolimod (July 2011). For the submission on dimethyl fumarate, the PBAC 
found the indirect comparison difficult to interpret given that two different drugs (glatiramer acetate and 
interferon beta-1a) were being used as the “common” comparator.  
Typically, results from indirect comparisons within submissions to the PBAC are used to support claims of non-
inferiority: that the proposed drug is no worse than its comparator. This was an issue mentioned by the PBAC in 
its review of cladribine where the PBAC noted the lack of justification for the method to calculate the minimum 
clinically important difference (MCID) used to assess non-inferiority. Similarly, in the first PSD for daclizumab 
(July 2016) the PBAC noted that a non-inferiority margin was not proposed in the submission and that non-
inferiority was claimed based on lack of a statistically significant difference. 
The PBAC did not always reject the results of indirect comparisons. For example, in the case of peginterferon 
beta-1A, the PBAC noted that the indirect comparison was appropriate given similar placebo event rates in both 
trials. 
3.2. Quality of life    
Another issue mentioned by the PBAC was the approach to quality of life adjustments used for quality-adjusted 
life year (QALY) estimation. This was noted in six PSDs: for four DMTs (natalizumab in November 2006, 
fingolimod in March 2011, cladribine in March 2011 and glatiramer in July 2017), and for both other drugs 
(fampridine in November 2012 and nabiximols in July 2013). Issues regarding quality of life included how 
utility values were obtained, and their application in the economic evaluation. 
In the submission for fampridine in 2012, the PBAC noted the base case ICER of $15,000 -$45,000 was most 
sensitive to the choice of utilities. Utilities were noted to be highly uncertain due to a range of calculations to 
base changes in utilities on changes in walking speed. This mapping exercise was indicated by PBAC to be 
“insufficiently reliable and highly variable”. The PBAC noted that there is no linear relationship between 
walking speed and utility, and that walking speed cannot be used as a proxy measure of quality of life. In the 
PSD for nabiximols (July 2013), the PBAC noted that disutilities of adverse events were not accounted for in 
the model, and utility values were used for three different strata of severity while there was no statistically 
significant difference between two of these strata.  
In the submission for natalizumab, utilities derived from Fisk et al. [14] were manipulated to allow their use in 
the economic model, but the approach could not be verified. In the PSD for fingolimod (March 2011), the 
PBAC noted that when a different source of utility values was used in the model, the ICER increased 
substantially.  
Regarding the application of utility values, the PSD for fingolimod (March 2011) discussed that the model used 
in the economic evaluation assumed a disutility associated with the need for frequent injections in case of 
treatment with existing DMTs. The ICER presented in the model was highly sensitive to this assumption. When 
disutility associated with injectable DMTs was removed from the economic model, the ICER increased from 
$45,000-$75,000 to $75,000-$105,000 per QALY gained. Assumed disutilities associated with the mode of 
administration were also addressed by the PBAC in the PSD for cladribine (March 2011). The PBAC did not 
think it feasible that the utility decrement associated with mode of administration would be approximately 
equivalent to the difference in utility applied for patients in EDSS 0 and 2 and greater than many utility 
differences between adjacent EDSS scores. In the PSD, it was not reported how sensitive the model results were 
to this assumption. In the model for glatiramer (July 2017), most of the health benefits were derived via quality 
of life improvements based on EDSS score progressions. The PBAC indicated that this lacked face validity 
given that a statistical difference in EDSS was not observed in the trial. 
 
3.3. Safety data 
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Another main issue identified by the PBAC was the lack of appropriate safety data, arising in the PSDs for 
cladribine (March 2011 and November 2017), peginterferon beta-1a (November 2014), alemtuzumab (July 
2014), teriflunomide (November 2012), daclizumab (July and November 2016) and ocrelizumab (July 2017).  
For cladribine, the PBAC noted that there were insufficient data to accurately assess the claim of non-inferior 
safety, and also referred to safety findings from the TGA, FDA (Food and Drug Administration) and CHMP 
(European Medicines Agency’s Committee for Medicinal for Human Use). In the PSD for alemtuzumab (July 
2014), the PBAC noted that there were no adequate data provided in the submission to support any claim of 
comparative safety to fingolimod or natalizumab. In the PSDs for ocrelizumab the PBAC also rejected the safety 
claims due to insufficient evidence. 
For various MS drugs, PSDs indicated a lack of longer term safety data. A lack of long-term safety data was 
mentioned for daclizumab, teriflunomide and peginterferon beta-1a. For the latter, the PBAC noted that longer 
term safety data beyond the 2-years reported in the submission were not available while MS treatment can span 
decades. Despite this issue, the PBAC indicated that the claim of non-inferior comparative safety of 
peginterferon beta-1a to interferon beta-1a was reasonable.  
 
3.4. Time horizon 
The last main issue addressed by the PBAC was the time horizon used in the economic models, arising in the 
submissions for fingolimod (March 2011), glatiramer (July 2017) and fampridine (November 2012). In the case 
of fingolimod (March 2011), the time horizon of the model was life-time, meaning that in the analyses patients 
were followed until death. Results were highly sensitive to changes in the model time horizon. When the model 
duration was reduced from 62 years to 5 years, it was found that the incremental cost per QALY gained 
increased to a range of $105,000 - $200,000 (in comparison to a base case incremental cost per QALY gained of 
$45,000 - $75,000). Results using a life-time horizon can be highly uncertain, due to uncertainty regarding the 
durability of treatment effects and differences between trial arms. Similarly, the glatiramer submission (July 
2017) extrapolated to an 80-year time horizon from 3 years of trial data. The PBAC indicated that this time 
horizon was likely to overestimate the net effect of early treatment. 
In the submission for fampridine (November 2012), the time horizon of the model was 5 years, with walking 
speed extrapolated from ≤14 weeks observed within the trial to a 5-year time horizon. The PBAC indicated that 
this was highly uncertain and noted that it potentially overestimated the treatment benefits of fampridine. 
 
4. Discussion 
This paper discussed key issues identified in PSDs regarding the Australian reimbursement of drugs indicated 
for MS. A key issue repeatedly identified by the PBAC as problematic in MS drug submissions relates to the 
validity of indirect comparisons; this issue was raised in eleven submissions. Differences between the study 
populations in clinical trials used for indirect comparison meant that the results were generally noted to be 
invalid. Another key issue for the PBAC was the validity of the approach used to obtain utilities, which was 
questioned in six PSDs. The PBAC noted that the utilities assumed in the model were inappropriately justified 
or not verifiable. Furthermore, safety issues were repeatedly noted by the PBAC: eight MS drug submissions 
lacked appropriate or long-term safety data beyond two years. Lastly, issues related to the time horizon used in 
the economic model were noted in three PSDs. These submissions were problematic in terms of extrapolation of 
results beyond the trial duration. 
While this study focused on the Australian reimbursement process, decision-makers in different countries have 
been known to make different decisions regarding the reimbursement of MS drugs. Also, decision makers can 
set special requirements for funding, or choose to implement managed entry or risk sharing arrangements. For 
example, in 2002, the UK NICE concluded that interferon beta and glatiramer acetate would be cost effective 
for MS only if the short-term disability benefits reported in clinical trials were maintained, and established a risk 
sharing scheme to assess whether disability progression was consistent with a cost-effectiveness target of £36 
000 per QALY projected over 20 years [15]. Interferon beta and glatiramer acetate were only recently approved 
for funding through the NHS, after price cuts [16]. 
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Recent literature suggests that stakeholders are uncertain about key issues which have resulted in heterogeneous 
reimbursement policies and varying levels of MS drug uptake (particularly for biosimilars) between different 
markets [17]. The current study relied on the evidence provided in PSDs. While PSDs aim to provide a 
comprehensive overview of the submission, its evaluation and the reimbursement decision, they may not 
address all issues that were discussed by the PBAC. More information on evaluation reports and correspondence 
between the sponsor, the department of health, and the PBAC could have provided additional insights into 
issues PBAC identified and discussed.  
Given that PSDs are publicly available, various authors have depended on them to analyse Australian 
reimbursement decisions. For example, Ngo [18] used PSDs to examine the likelihood of reimbursement given a 
drug’s ICER. Chim et al. [7] and Wonder & Chin [19] examined whether drugs for certain types of conditions 
(cancer and orphan diseases, respectively) are more or less likely to receive a positive reimbursement decision 
than other drugs. These studies found that while PBAC is not bound by any absolute decision rule, it is possible 
to identify factors which increase the probability of being accepted for reimbursement. 
Similar to the current study, Wonder and Dunlop [4] used PSDs to identify problems related to the quality of the 
clinical evidence in submissions to the PBAC. They did not perform a detailed analysis of the issues in one 
disease area (like MS) but performed a more general analysis of all submissions considered by the PBAC 
between 2005 and 2012. Their results corroborate our MS specific findings - that the clinical evidence used in 
submissions was “rather poor fit for purpose” [4]. According to Wonder and Dunlop, one in every two 
submissions to the PBAC had a significant problem with the supporting clinical evidence. The type of problems 
were not reported on in depth, so it is not possible to determine to what extent the specific issues discussed in 
our article were common in disease areas other than MS.  
Given that the PBAC has repeatedly identified the same issues in MS drug submissions, more attention by drug 
developers and/or clinical trialists to these issues for MS drugs is required. Learning from published experience 
with other drugs indicated for MS, sponsors can limit the potential for rejection by providing the required 
information ahead of time. Some problems might be prevented at the trial development stage, by choosing the 
right comparator and measuring the right outcomes (incl. quality of life, adverse effects, etc.) over the right 
period of time. The current article can be used to inform these choices for the Australian situation. However, it 
is recognised that Australia is only a small part of the global market for pharmaceuticals, and Australian 
reimbursement requirements may not be key in determining global clinical trial protocols. 
In many countries, full access and reimbursement of MS treatments is far from achieved and prevents patients 
benefiting from the remarkable progress that has been made in MS drugs [20]. Improved design and use of 
clinical studies and economic evaluations may partially alleviate these issues and might result in higher approval 
rates for reimbursement.  
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